UroGen Pharma to Present at Upcoming Investor Conferences

Rhea-AI Summary

UroGen Pharma (Nasdaq: URGN), a biotechnology company focused on urothelial and specialty cancer treatments, has announced its participation in three upcoming investor conferences in September 2025.

The company will participate in fireside chat sessions at the Wells Fargo Healthcare Conference in Boston on September 3rd at 2:15 PM ET, the Cantor Fitzgerald Global Healthcare Conference in New York on September 4th at 3:55 PM ET, and the H.C. Wainwright Global Healthcare Conference in New York on September 8th at 9:00 AM ET.

Webcasts will be accessible through UroGen's Investor Relations website, with replays available for approximately 90 days after each event.

PRINCETON, N.J., Aug. 21, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in the following investor conferences in September.

Wells Fargo Healthcare Conference

Date / Time:	September 3rd, at 2:15 PM ET
Format:	Fireside Chat
Location:	Boston, MA

Cantor Fitzgerald Global Healthcare Conference

Date / Time:	September 4th, at 3:55 PM ET
Format:	Fireside Chat
Location:	New York, NY

H.C. Wainwright 27^th Annual Global Healthcare Conference

Date / Time:	September 8th, at 9:00 AM ET
Format:	Fireside Chat
Location:	New York, NY

The conference webcasts will be available through the Events section of the Company’s Investor Relations website. Replays will be available for approximately 90 days following the event.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product is approved to treat low-grade upper tract urothelial cancer, and our second product is the first and only FDA-approved medication for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Both medicines are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on X (Twitter), @UroGenPharma.

INVESTORS:

Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093

MEDIA:

Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3583 ext. 1083

FAQ

When is UroGen Pharma (URGN) presenting at the Wells Fargo Healthcare Conference 2025?

UroGen Pharma will present at the Wells Fargo Healthcare Conference on September 3rd, 2025 at 2:15 PM ET in Boston, MA.

How can investors access UroGen Pharma's (URGN) conference presentations in September 2025?

Investors can access the webcasts through the Events section of UroGen's Investor Relations website. Replays will be available for approximately 90 days after each event.

Which investor conferences is UroGen Pharma (URGN) attending in September 2025?

UroGen Pharma is attending three conferences: the Wells Fargo Healthcare Conference (Sept 3), Cantor Fitzgerald Global Healthcare Conference (Sept 4), and H.C. Wainwright Global Healthcare Conference (Sept 8).

What is the format of UroGen Pharma's (URGN) presentations at the September 2025 conferences?

All presentations will be in a fireside chat format at each of the three healthcare conferences.